All the news Showing 10 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources France switches to simplified pangenotypic hepatitis C treatment Keith Alcorn / 05 June 2019 French health authorities have recommended that everyone diagnosed with hepatitis C should be treated with a pangenotypic direct-acting antiviral combination by a general practitioner unless they have severe liver disease, co-infection or kidney ... Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... 8 weeks of Maviret cures 98% of people with hepatitis C and cirrhosis Keith Alcorn / 14 November 2018 An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of ... New EASL hepatitis C recommendations emphasise simplicity Liz Highleyman / 23 April 2018 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment recommendations at the 2018 International Liver Congress this month in Paris. The guidelines are available online in ... HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... 8-week treatment for hepatitis C with Maviret highly effective in people without cirrhosis Keith Alcorn / 13 April 2018 An eight-week course of treatment with the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C infection in people without cirrhosis, results of two real-world studies presented at the ... Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy Keith Alcorn / 12 April 2018 An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ... New affordable hepatitis C combination shows 97% cure rate Keith Alcorn / 12 April 2018 The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and ... Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV Liz Highleyman / 28 November 2017 An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according ... Hepatitis C halved in Spanish people living with HIV in one year due to treatment Keith Alcorn / 27 October 2017 Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid, reported on Friday at the ... ← First12345...23Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive